Review



ng well recombinant sars cov 2 spike protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems ng well recombinant sars cov 2 spike protein
    Ng Well Recombinant Sars Cov 2 Spike Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ng+well+recombinant+sars+cov+2+spike+protein/Recombinant+SARS-CoV-2+Spike+His+Protein%2C+CF/pm41893460-77-12-17
    Average 95 stars, based on 72 article reviews
    ng well recombinant sars cov 2 spike protein - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: SARS-CoV-2 Anti-Spike IgG Subclass Titres in a Population with Prior Exposure to Perfluorooctanoic Acid (PFOA).
    Article Snippet: .. Briefly, high-binding plates (Greiner Bio-One GmbH, Kremsmünster, Austria) were coated with 100 ng/well recombinant SARS-CoV-2 spike protein (R&D Systems, Minneapolis, MN, USA) suspended in coating buffer (8.4 g/L NaHCO3; 3.56 g/L Na2CO3 in H2O; pH = 9.6). ..



    Similar Products

    ng well s1 protein  (Sino Biological)
    95
    Sino Biological ng well s1 protein
    Ng Well S1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ng+well+recombinant+sars+cov+2+spike+protein/SARS-CoV-2+(2019-nCoV)+Spike+S1-His+Recombinant+Protein/pm36792434-81-8-12
    Average 95 stars, based on 1 article reviews
    ng well s1 protein - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    ng well recombinant sars cov 2 spike protein  (R&D Systems)
    95
    R&D Systems ng well recombinant sars cov 2 spike protein
    Ng Well Recombinant Sars Cov 2 Spike Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ng+well+recombinant+sars+cov+2+spike+protein/Recombinant+SARS-CoV-2+Spike+His+Protein%2C+CF/pm41893460-77-12-17
    Average 95 stars, based on 1 article reviews
    ng well recombinant sars cov 2 spike protein - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    well recombinant sars cov 2 spike  (Sino Biological)
    95
    Sino Biological well recombinant sars cov 2 spike
    Well Recombinant Sars Cov 2 Spike, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ng+well+recombinant+sars+cov+2+spike+protein/SARS-CoV+Spike+S2-His+Recombinant+Protein/pm37993332-125-13-20
    Average 95 stars, based on 1 article reviews
    well recombinant sars cov 2 spike - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    10 ng/well recombinant e. coli -produced sars-cov-2 spike protein  (Thermo Fisher)
    90
    Thermo Fisher 10 ng/well recombinant e. coli -produced sars-cov-2 spike protein
    Construction of recombinant LSDV-SARS2-S,N. ( A ) Schematic diagrams of the wild type and modified <t>SARS-CoV-2</t> spike antigens with amino acid residue positions labeled above. The native signal sequence (SS) was replaced with the tissue plasminogen activator signal sequence (TPA), the furin cleavage site (RRAR) was replaced with a short linker sequence (GSAS), and two stabilizing proline mutations were included (K986P and V987P). ( B ) Schematic diagram of the transfer vector LSDV-Red SARS-CoV2-S+N used for homologous recombination with the parent virus LSDV(SODis)BEFV-Gb genome between ORFs 49 and 50 to generate LSDV-SARS2-S,N. ( C ) Generation and passage of LSDV-SARS2-S,N. The recombinant virus (mCherry; red) was constructed in LT cells at passage 0 (P0) by infection with LSDV(SODis)BEFV-Gb (eGFP; green) and transfection with the transfer vector. P1 = first passage in MDBK cells, P2 = second passage in MDBK cells, P3 = third passage in MDBK cells. All scale bars = 50 µm.
    10 Ng/Well Recombinant E. Coli Produced Sars Cov 2 Spike Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ng+well+recombinant+sars+cov+2+spike+protein/pmc10383203-107-12-15
    Average 90 stars, based on 1 article reviews
    10 ng/well recombinant e. coli -produced sars-cov-2 spike protein - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Construction of recombinant LSDV-SARS2-S,N. ( A ) Schematic diagrams of the wild type and modified SARS-CoV-2 spike antigens with amino acid residue positions labeled above. The native signal sequence (SS) was replaced with the tissue plasminogen activator signal sequence (TPA), the furin cleavage site (RRAR) was replaced with a short linker sequence (GSAS), and two stabilizing proline mutations were included (K986P and V987P). ( B ) Schematic diagram of the transfer vector LSDV-Red SARS-CoV2-S+N used for homologous recombination with the parent virus LSDV(SODis)BEFV-Gb genome between ORFs 49 and 50 to generate LSDV-SARS2-S,N. ( C ) Generation and passage of LSDV-SARS2-S,N. The recombinant virus (mCherry; red) was constructed in LT cells at passage 0 (P0) by infection with LSDV(SODis)BEFV-Gb (eGFP; green) and transfection with the transfer vector. P1 = first passage in MDBK cells, P2 = second passage in MDBK cells, P3 = third passage in MDBK cells. All scale bars = 50 µm.

    Journal: Viruses

    Article Title: LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters

    doi: 10.3390/v15071409

    Figure Lengend Snippet: Construction of recombinant LSDV-SARS2-S,N. ( A ) Schematic diagrams of the wild type and modified SARS-CoV-2 spike antigens with amino acid residue positions labeled above. The native signal sequence (SS) was replaced with the tissue plasminogen activator signal sequence (TPA), the furin cleavage site (RRAR) was replaced with a short linker sequence (GSAS), and two stabilizing proline mutations were included (K986P and V987P). ( B ) Schematic diagram of the transfer vector LSDV-Red SARS-CoV2-S+N used for homologous recombination with the parent virus LSDV(SODis)BEFV-Gb genome between ORFs 49 and 50 to generate LSDV-SARS2-S,N. ( C ) Generation and passage of LSDV-SARS2-S,N. The recombinant virus (mCherry; red) was constructed in LT cells at passage 0 (P0) by infection with LSDV(SODis)BEFV-Gb (eGFP; green) and transfection with the transfer vector. P1 = first passage in MDBK cells, P2 = second passage in MDBK cells, P3 = third passage in MDBK cells. All scale bars = 50 µm.

    Article Snippet: ELISA plates were coated overnight with 10 ng/well recombinant E. coli -produced SARS-CoV-2 spike protein (Invitrogen, RP-87668).

    Techniques: Recombinant, Modification, Residue, Labeling, Sequencing, Plasmid Preparation, Homologous Recombination, Virus, Construct, Infection, Transfection

    Immunogenicity of LSDV-SARS2-S,N in mice. ( A ) Schematic of the timing of immunizations and blood draws. ( B ) Frequency of antigen-specific T cells recognizing SARS-CoV-2 peptide pools. (SFU, spot-forming units). ( C ) Quantification of spike-specific antibodies by ELISA over the course of the experiment. The antibody titers are presented for pooled sera at each time point. ( D ) Terminal neutralizing antibody titers against the matched virus from which the vaccines were derived. (ID 50 , half maximal inhibitory dilution).

    Journal: Viruses

    Article Title: LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters

    doi: 10.3390/v15071409

    Figure Lengend Snippet: Immunogenicity of LSDV-SARS2-S,N in mice. ( A ) Schematic of the timing of immunizations and blood draws. ( B ) Frequency of antigen-specific T cells recognizing SARS-CoV-2 peptide pools. (SFU, spot-forming units). ( C ) Quantification of spike-specific antibodies by ELISA over the course of the experiment. The antibody titers are presented for pooled sera at each time point. ( D ) Terminal neutralizing antibody titers against the matched virus from which the vaccines were derived. (ID 50 , half maximal inhibitory dilution).

    Article Snippet: ELISA plates were coated overnight with 10 ng/well recombinant E. coli -produced SARS-CoV-2 spike protein (Invitrogen, RP-87668).

    Techniques: Enzyme-linked Immunosorbent Assay, Virus, Vaccines, Derivative Assay

    Vaccine-mediated protection against heterologous challenge. ( A ) Change in weight following experimental challenge with SARS-CoV-2 Delta (10 4 pfu) 2-way ANOVA. * = p < 0.05 ( B ) Grading of lung pathology following challenge (t-test). ( C ) Representative images of histopathology findings in lung sections. Scale bars = 50 µm. ( D ) SARS-CoV-2 RNA viral load in the lungs, following challenge (t-test).

    Journal: Viruses

    Article Title: LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters

    doi: 10.3390/v15071409

    Figure Lengend Snippet: Vaccine-mediated protection against heterologous challenge. ( A ) Change in weight following experimental challenge with SARS-CoV-2 Delta (10 4 pfu) 2-way ANOVA. * = p < 0.05 ( B ) Grading of lung pathology following challenge (t-test). ( C ) Representative images of histopathology findings in lung sections. Scale bars = 50 µm. ( D ) SARS-CoV-2 RNA viral load in the lungs, following challenge (t-test).

    Article Snippet: ELISA plates were coated overnight with 10 ng/well recombinant E. coli -produced SARS-CoV-2 spike protein (Invitrogen, RP-87668).

    Techniques: Histopathology